01 /What warning levels are
Every peptide in the Apothify library carries a warning level on a 1 to 3 scale. The number is shown as L1, L2, or L3 on the peptide page, on result cards in the finder and compare tools, and in the cart and emails.
Warning levels are an editorial judgment, not a regulatory designation. They synthesize handling complexity, the breadth of published safety data, and the typical scrutiny the peptide attracts in research and compliance contexts. The level is set by Apothify's compliance team and reviewed when new data emerges.
02 /Level 1 , entry, well studied
L1 peptides are well studied compounds with a long publication history, conservative handling requirements, and a broad consensus on what they are and how they behave in standard research models. Examples in the Apothify library include Carnosine, Anserine, Acetyl Carnosine, Glutathione, and most of the cosmetic peptide family.
These are reasonable starting points for researchers new to peptide work. They tolerate ordinary laboratory conditions, the published literature is large, and the typical experimental window is forgiving.
03 /Level 2 , moderate
L2 peptides have elevated handling notes. They may require more careful temperature control, may have a narrower stability window, may interact with related compounds in ways that require attention, or may have a smaller published literature base. The majority of the Apothify library is L2.
Examples include the GHRH and GHRP family (CJC 1295, Ipamorelin, Sermorelin, GHRP 2, GHRP 6, Hexarelin), most thymic peptides (Thymalin, Thymogen), and most Russian bioregulator entries.
L2 is a normal working level for researchers with prior peptide handling experience. Read the safety and interactions section on every L2 peptide page before planning a protocol.
04 /Level 3 , for experienced researchers only
L3 peptides require specialized handling, have narrower safety windows, attract more compliance scrutiny, or fall in research categories where the regulatory landscape is actively evolving. The number of L3 entries in the Apothify library is intentionally small.
Examples include the GLP family (Semaglutide, Tirzepatide, Retatrutide, Liraglutide), IGF 1 LR3, Melanotan II, the opioid peptides Endomorphin 1 and Endomorphin 2, and several growth hormone secretagogues with limited published safety data (MK 677, Tabimorelin, Anamorelin).
L3 is not a recommendation for or against the peptide. It is a signal to read every section carefully, to verify the handling protocol independently, and to confirm institutional compliance before ordering.
05 /How warning level interacts with the peptide finder
The finder lets the user set a complexity tolerance during the wizard. Step 3 asks how far up the warning scale you are willing to consider, with options L1 only, L1 to L2, or any level. The scoring engine then filters out any peptide above the chosen ceiling before ranking matches.
Setting the ceiling at L1 returns only the most conservative options. Setting it at L1 to L2 is the default. Setting it to any level returns the full library. The setting is per finder session and does not change the underlying library.
06 /Warning level and the SAFE or ELEVATED commerce distinction
Warning level (1 to 3) and regulatory status (SAFE or ELEVATED) are separate axes. SAFE means Apothify offers the peptide as a research product. ELEVATED means Apothify lists the peptide for encyclopedia coverage only, with no cart, no checkout, and no price. A peptide can be SAFE L1, SAFE L2, ELEVATED L1, or ELEVATED L3 in any combination.
In practice, ELEVATED entries skew toward L2 and L3, but the dimensions are independent. A peptide may be ELEVATED for a regulatory reason while still being L1 from a handling standpoint.
07 /How the level is set
Apothify reviews several inputs when setting a warning level: the size and quality of the published peer reviewed literature, the handling notes from the manufacturer's COA, the receptor selectivity and known off target profile, the typical research protocols documented in literature, the regulatory landscape (FDA, WADA, foreign regulators), and any past safety signal in published research models.
The level can be changed when new data emerges. Apothify aims to review the full library every quarter and adjust warning levels where the literature has moved. When a level changes, the peptide page reflects the new value immediately; existing orders carry the level that was in effect at purchase.
08 /How to use warning level in protocol planning
Treat the warning level as one input, not the answer. The safety and interactions section on the peptide page contains the specific notes. The research notes section covers handling specifics like reconstitution and storage. The compare tool flags known interactions between any two peptides you put side by side.
If a peptide is L3 and your protocol involves combination work with another L3, that combination warrants particular care. The compare tool will surface any caution rated interaction in that case.
09 /What warning level is not
Warning level is not a potency rating. A higher number does not mean a stronger compound. It means more careful handling.
Warning level is not a recommendation. Apothify does not recommend peptides for any use. Every peptide is sold for laboratory research use only.
Warning level is not a regulatory designation. The FDA, WADA, EMA, and analogous foreign agencies use their own classification systems. The Apothify warning level is editorial.
